(Q37872258)

24 August 2017

1 reference

title

Therapeutic plasma proteins--application of proteomics in process optimization, validation, and analysis of the final product (English)

1 reference

24 August 2017

Dajana Gaso-Sokac

1

1 reference

24 August 2017

Spomenka Kovac

series ordinal

2

1 reference

24 August 2017

James Clifton

series ordinal

3

1 reference

24 August 2017

Djuro Josic

series ordinal

4

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

32

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

1104-1117

1 reference

Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Vitronectin in clotting factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Application of proteomics in biotechnology--microbial proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomics as a tool for optimization of human plasma protein separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Transfusion medicine in the era of proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Use of proteomics for validation of the isolation process of clotting factor IX from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Genomics and proteomics in process development: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Degradation products of factor VIII which can lead to increased immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Update on pathogen reduction technology for therapeutic plasma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Antithrombin III (AT) and recombinant tissue plasminogen activator (R-TPA) used singly and in combination versus supportive care for treatment of endotoxin-induced disseminated intravascular coagulation (DIC) in the neonatal pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The promise and challenges of bioengineered recombinant clotting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Posttranslational modifications of recombinant myotube-synthesized human factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Modern plasma fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Plasma for fractionation: safety and quality issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

A comparison of methods of pathogen inactivation of FFP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Solvent/detergent-treated plasma: composition, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recent advances in blood-related proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The human plasma proteome: history, character, and diagnostic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Isolation of esterified fatty acids bound to serum albumin purified from human plasma and characterised by MALDI mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Overexpression of heat shock proteins (HSPs) in CHO cells for extended culture viability and improved recombinant protein production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Anticomplementary activity of IVIG concentrates--important assay parameters and impact of IgG polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomic analysis for process development and control of therapeutic protein separation from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

IgG glycosylation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Biochemistry and genetics of von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Use of high-resolution techniques for the characterization of clotting factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Quantitative Comparison of Global Carbohydrate Structures of Glycoproteins Using LC−MS and In-Source Fragmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Concentrate safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Potency and mass of factor VIII in FVIII products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Factor VIII and von Willebrand factor--too sweet for their own good

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of a recombinant antihaemophilia-A factor (factor VIII-delta II) by matrix-assisted laser desorption/ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of tyrosine sulfate residues in antihemophilic recombinant factor VIII by liquid chromatography electrospray ionization tandem mass spectrometry and amino acid analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The protein structure and effect of factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

The molecular basis of factor V and VIII procofactor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Trp2313-His2315 of Factor VIII C2 Domain Is Involved in Membrane Binding: STRUCTURE OF A COMPLEX BETWEEN THE C2 DOMAIN AND AN INHIBITOR OF MEMBRANE BINDING

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

A comparison of nano-electrospray gas-phase electrophoretic mobility macromolecular analysis and matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometry for the characterization of the recombinant coagulation glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Implementation of an FTIR calibration curve for fast and objective determination of changes in protein secondary structure during formulation development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of factor VIII pharmaceutical preparations by means of MudPIT proteomic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Structure-function relationships in factor IX and factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recombinant factor IX for clinical and research use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Two novel mutations in EGF-like domains of human factor IX dramatically impair intracellular processing and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Scanning the cell surface proteome of cancer cells and identification of metastasis-associated proteins using a subtractive immunization strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Fibrin glue and clinical impact on haemophilia care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Molecular recognition mechanisms of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Sample displacement chromatography of Atlantic Salmon (Salmo salar) thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

A combined structural dynamics approach identifies a putative switch in factor VIIa employed by tissue factor to initiate blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Separation of active and inactive forms of human antithrombin by heparin affinity chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Determination of the site-specific and isoform-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC-ESI-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

On the variation of glycosylation in human plasma derived antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of antithrombin III from human plasma by two-dimensional gel electrophoresis and capillary electrophoretic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of glyco isoforms in plasma-derived human antithrombin by on-line capillary zone electrophoresis-electrospray ionization-quadrupole ion trap-mass spectrometry of the intact glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Development of a peptide mapping procedure to identify and quantify methionine oxidation in recombinant human alpha1-antitrypsin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Glycoproteomic characterization of butyrylcholinesterase from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications-comprehensive analysis of beta-casein and epidermal growth factor receptor (E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Glycation of interferon-beta-1b and human serum albumin in a lyophilized glucose formulation. Part III: application of proteomic analysis to the manufacture of biological drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

Application of proteomics to hematology: the revolution is starting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Recombinant clotting factors.

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

High-throughput screening of chromatographic separations: I. Method development and column modeling

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Fragmentation of therapeutic human immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Treatment of von Willebrand disease

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

New electric method to determine enzymatic activity. Determination of antithrombin in whole blood

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Proteomic characterization of inter-alpha inhibitor proteins from human plasma

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Human pre-alpha-inhibitor: isolation from a by-product of industrial scale plasma fractionation and structural analysis of its H3 heavy chain

1 reference

https://api.crossref.org/works/10.1002%2FELPS.201000641

7 January 2021

Identifiers

DOI

10.1002/ELPS.201000641

1 reference

24 August 2017

1 reference